Oncologix Tech (OTCMKTS:OCLG) and Becton Dickinson and (NYSE:BDX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.
Volatility & Risk
Oncologix Tech has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Becton Dickinson and has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.
This is a summary of current recommendations for Oncologix Tech and Becton Dickinson and, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Becton Dickinson and||0||3||5||1||2.78|
Becton Dickinson and has a consensus target price of $267.00, suggesting a potential upside of 2.42%. Given Becton Dickinson and’s higher possible upside, analysts clearly believe Becton Dickinson and is more favorable than Oncologix Tech.
This table compares Oncologix Tech and Becton Dickinson and’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Becton Dickinson and||6.84%||15.52%||6.32%|
Earnings & Valuation
This table compares Oncologix Tech and Becton Dickinson and’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Becton Dickinson and||$17.29 billion||4.08||$1.23 billion||$11.68||22.32|
Becton Dickinson and has higher revenue and earnings than Oncologix Tech.
Institutional & Insider Ownership
84.5% of Becton Dickinson and shares are owned by institutional investors. 39.9% of Oncologix Tech shares are owned by insiders. Comparatively, 0.1% of Becton Dickinson and shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Becton Dickinson and beats Oncologix Tech on 8 of the 10 factors compared between the two stocks.
Oncologix Tech Company Profile
Oncologix Tech, Inc., a diversified medical holding company, provides health care services in the United States. It offers personal home care services, including daily living assistance, companionship, and homemaker services, as well as Alzheimer's care, home care resource planning, and medical care coordination services. The company also manufactures, markets, and distributes medical technologies and products for skilled nursing facilities, acute and critical care facilities, assisted living facilities, hospitals and medical institutions, federal agencies, home medical care industry, respiratory and therapy- physical/occupational therapy centers. In addition, it distributes and sells home medical equipment for sleep and respiratory therapies; supplies and services durable medical equipment to treat obstructive Sleep Apnea; C-PAP and BiPAP oxygen equipment, a large selection of mask interfaces; and offers personalized treatment plans, as well as monitoring and support services. The company was formerly known as BestNet Communications Corp. and changed its name to Oncologix Tech, Inc. in January 2007. Oncologix Tech, Inc. was founded in 1995 and is based in Lafayette, Louisiana.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, monoclonal antibodies and kits, reagent systems, bench-side solutions, and molecular indexing and next-generation sequencing sample preparation products, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, thoracic and abdominal drainage, and surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Receive News & Ratings for Oncologix Tech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncologix Tech and related companies with MarketBeat.com's FREE daily email newsletter.